23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST
2024-11-27 | Pages: 200+ | Report ID: MD-R-2024-11-27-17094 | Healthcare
Historical data: 2018 - 2023
Forecast period: 2024 - 2031
Quantitative units: Revenue in USD million and CAGR from 2024 to 2031
Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends
23-Valent Pneumococcal Polysaccharide Vaccine Market
1.1 SCOPE OF THE REPORT
1.2 MARKET SEGMENT ANALYSIS
1.3 REGULATORY SCENARIO BY REGION/COUNTRY
1.4 MARKET INVESTMENT SCENARIO STRATEGIC
1.5 MARKET ANALYSIS BY TYPE (USD MILLION)
1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)
2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS
2.1.1 MARKET DRIVER ANALYSIS
2.1.2 MARKET RESTRAINT ANALYSIS
2.1.3 MARKET OPPORTUNITY
2.1.4 MARKET CHALLENGES
3.1 INDUSTRY TRENDS
3.1.1 SWOT ANALYSIS
3.1.2 PESTEL ANALYSIS
3.1.3 PORTER’S FIVE FORCES ANALYSIS
3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS
4.1 COVID-19 ANALYSIS
5.1 GLOBAL 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET, SALES AREA, TYPE
5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET
7.1 GLOBAL 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE (2018-2031) (USD MILLION)
8.1 GLOBAL 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
8.2 GLOBAL 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
9.1 GLOBAL 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
9.2 GLOBAL 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
10.1 GLOBAL 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)
10.2 GLOBAL 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)
11.1 NORTH AMERICA 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
11.2 NORTH AMERICA 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
11.3 NORTH AMERICA 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
11.4 NORTH AMERICA 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
11.5 NORTH AMERICA 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
11.6 NORTH AMERICA 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
12.1 EUROPE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
12.2 EUROPE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
12.3 EUROPE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
12.4 EUROPE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
12.5 EUROPE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
12.6 EUROPE 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
13.1 ASIA PACIFIC 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
13.2 ASIA PACIFIC 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
13.3 ASIA PACIFIC 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
13.4 ASIA PACIFIC 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
13.5 ASIA PACIFIC 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
13.6 ASIA PACIFIC 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
14.1 LATIN AMERICA 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>
14.2 LATIN AMERICA 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
14.3 LATIN AMERICA 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
14.4 LATIN AMERICA 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
14.5 LATIN AMERICA 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
14.6 LATIN AMERICA 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)
15.1 MIDDLE EAST & AFRICA 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)
15.2 MIDDLE EAST & AFRICA 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)
15.3 MIDDLE EAST & AFRICA 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)
15.4 MIDDLE EAST & AFRICA 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)
15.5 MIDDLE EAST & AFRICA 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)
15.6 MIDDLE EAST & AFRICA 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>
16.1 Baxter International Inc
16.1.1 COMPANY DETAILS
16.1.2 FINANCIALS (USD MILLION)
16.1.3 PRODUCT SUMMARY
16.1.4 RECENT DEVELOPMENTS
16.2 Beijing Minhai Biotechnology
16.3 Sanofi SA
16.4 Serum Institute of India
16.5 Biogen Inc
16.6 Eli Lilly and Company
16.7 Pfizer Inc
16.8 GlaxoSmithKline Plc
16.9 Merck & Co
16.10 AstraZeneca
18.1 METHODOLOGY
18.2 RESEARCH DATA SOURCE
18.2.1 SECONDARY DATA
18.2.2 KEY DATA FROM SECONDARY
18.2.3 PRIMARY DATA
18.2.4 KEY DATA FROM PRIMARY
18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS
18.2.6 MARKET ESTIMATION
18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH
18.2.8 LEGAL DISCLAIMER
Market Segments
By TypeSingle Dose Vial
Pre-filled Syringe
By Application
For Children (2-10)
For Person (10-64)
For The old (=65)
Companies
Baxter International Inc
Beijing Minhai Biotechnology
Sanofi SA
Serum Institute of India
Biogen Inc
Eli Lilly and Company
Pfizer Inc
GlaxoSmithKline Plc
Merck & Co
AstraZeneca
BROWSE INDUSTRY
- PROACTIVE
- QUALITY & RELIABILITY
- GLOBAL OUTREACH
- COMPETITIVE PRICING
WHY CHOOSE US
We manage our resources 24/7 to identify issues and address them before they become problems.
We are committed to providing reliable and highly accurate data with an excellent quality control system.
6 Major regions and 40+ countries level analysis accomplished.
Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.